X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (1548) 1548
science & technology (1433) 1433
life sciences & biomedicine (1355) 1355
male (1249) 1249
animals (1193) 1193
female (997) 997
pancreatic neoplasms - chemically induced (933) 933
pancreatic cancer (805) 805
pancreatic neoplasms - pathology (790) 790
oncology (719) 719
pancreatic neoplasms - drug therapy (662) 662
middle aged (585) 585
aged (537) 537
cricetinae (410) 410
rats (406) 406
adult (390) 390
cancer (353) 353
mesocricetus (320) 320
mice (313) 313
pancreatic neoplasms - metabolism (308) 308
deoxycytidine - analogs & derivatives (304) 304
cell line, tumor (249) 249
abridged index medicus (224) 224
pancreatic neoplasms - genetics (223) 223
carcinogens (216) 216
adenocarcinoma - drug therapy (202) 202
antineoplastic combined chemotherapy protocols - therapeutic use (200) 200
nitrosamines (197) 197
deoxycytidine - adverse effects (195) 195
pancreas (191) 191
pancreas - pathology (190) 190
research (189) 189
chemotherapy (185) 185
adenocarcinoma - chemically induced (178) 178
gemcitabine (174) 174
neoplasms, experimental - chemically induced (174) 174
antineoplastic combined chemotherapy protocols - adverse effects (173) 173
treatment outcome (173) 173
gastroenterology & hepatology (172) 172
adenocarcinoma - pathology (166) 166
tumors (165) 165
deoxycytidine - administration & dosage (159) 159
care and treatment (154) 154
aged, 80 and over (153) 153
disease models, animal (151) 151
risk factors (150) 150
time factors (149) 149
metastasis (148) 148
apoptosis (146) 146
pancreas - drug effects (143) 143
analysis (142) 142
pharmacology & pharmacy (141) 141
research article (141) 141
medicine & public health (138) 138
health aspects (134) 134
antimetabolites, antineoplastic - adverse effects (129) 129
nitrosamines - toxicity (127) 127
proteins (116) 116
pancreatic neoplasms - mortality (112) 112
gene expression (110) 110
dose-response relationship, drug (109) 109
deoxycytidine - therapeutic use (108) 108
antineoplastic agents - therapeutic use (107) 107
neutropenia - chemically induced (105) 105
pancreatic neoplasms - complications (102) 102
cell biology (101) 101
pancreatic neoplasms - diagnosis (101) 101
cancer therapies (100) 100
carcinogens - toxicity (100) 100
pancreatic neoplasms - prevention & control (100) 100
adenocarcinoma (99) 99
drug administration schedule (99) 99
pancreatic neoplasms - epidemiology (98) 98
antineoplastic agents - adverse effects (96) 96
endocrinology & metabolism (93) 93
pancreatic neoplasms (91) 91
kinases (88) 88
pancreatitis (88) 88
pancreatitis - chemically induced (88) 88
cell proliferation (87) 87
development and progression (87) 87
medicine (85) 85
fluorouracil - administration & dosage (84) 84
neoplasm metastasis (84) 84
studies (83) 83
adenoma - chemically induced (81) 81
cancer research (81) 81
mutation (81) 81
immunohistochemistry (80) 80
mice, nude (79) 79
disease progression (78) 78
tumor cells, cultured (78) 78
antimetabolites, antineoplastic - therapeutic use (77) 77
signal transduction (77) 77
liver neoplasms - secondary (76) 76
pancreatic neoplasms - etiology (76) 76
pancreatic neoplasms - surgery (75) 75
biochemistry & molecular biology (74) 74
precancerous conditions - chemically induced (74) 74
science & technology - other topics (74) 74
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (2309) 2309
Japanese (80) 80
German (34) 34
French (31) 31
Spanish (8) 8
Chinese (7) 7
Italian (5) 5
Dutch (4) 4
Russian (3) 3
Hebrew (2) 2
Norwegian (2) 2
Swedish (2) 2
Danish (1) 1
Hungarian (1) 1
Lithuanian (1) 1
Polish (1) 1
Portuguese (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The lancet oncology, ISSN 1470-2045, 06/2017, Volume 18, Issue 6, pp. 770 - 778
Summary Background Pancreatic cancer statistics are dismal, with a 5-year survival of less than 10%, and more than 50% of patients presenting with metastatic... 
Hematology, Oncology and Palliative Medicine | Life Sciences & Biomedicine | Oncology | Science & Technology | Leucovorin - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Sulfides - administration & dosage | Pancreatic Neoplasms - drug therapy | Organoplatinum Compounds - administration & dosage | Fluorouracil - administration & dosage | Hyperglycemia - chemically induced | Leucovorin - adverse effects | Fluorouracil - adverse effects | Hypokalemia - chemically induced | Camptothecin - administration & dosage | Female | Neutropenia - chemically induced | Camptothecin - analogs & derivatives | Camptothecin - adverse effects | Hematologic Diseases - chemically induced | Sensation Disorders - chemically induced | Abdominal Pain - chemically induced | Pancreatic Neoplasms - pathology | Anemia - chemically induced | Thrombocytopenia - chemically induced | Adenocarcinoma - drug therapy | Adenocarcinoma - secondary | Hypoalbuminemia - chemically induced | Maximum Tolerated Dose | Sepsis - chemically induced | Sulfides - adverse effects | Aged | Caprylates - administration & dosage | Caprylates - adverse effects | Organoplatinum Compounds - adverse effects | Lymphopenia - chemically induced | Enzymes | Medical colleges | Care and treatment | Metastasis | Antineoplastic agents | Cells | Antimitotic agents | Cancer patients | Chemotherapy | Pancreatic cancer | Physiological aspects | Product development | Cancer | Index Medicus
Journal Article
European Journal of Cancer, ISSN 0959-8049, 2016, Volume 68, pp. 1 - 10
Abstract Purpose We performed a multi-centre phase I study to assess the safety, pharmacokinetics (PK) and pharmacodynamics (PD) of the orally available small... 
Hematology, Oncology and Palliative Medicine | Pharmacodynamics | MEK inhibitor | Phase I | Optimal biological dose | Pharmacokinetics | Life Sciences & Biomedicine | Oncology | Science & Technology | Lung Neoplasms - drug therapy | Pancreatic Neoplasms - metabolism | Nausea - chemically induced | Allosteric Regulation | Humans | Lung Neoplasms - metabolism | Middle Aged | Male | Fatigue - chemically induced | Ribosomal Protein S6 Kinases, 70-kDa - drug effects | Protein Kinase Inhibitors - adverse effects | Colorectal Neoplasms - drug therapy | Chromatography, Liquid | Proto-Oncogene Proteins c-akt - metabolism | MAP Kinase Kinase 1 - antagonists & inhibitors | Bile Duct Neoplasms - metabolism | Ribosomal Protein S6 Kinases, 70-kDa - metabolism | Administration, Oral | Carcinoma, Non-Small-Cell Lung - metabolism | Neoplasms - drug therapy | Maximum Tolerated Dose | Mesothelioma - metabolism | Mitogen-Activated Protein Kinase 3 - metabolism | Anorexia - chemically induced | Glycogen Synthase Kinase 3 beta - drug effects | Mitogen-Activated Protein Kinase 1 - metabolism | Neoplasms - metabolism | Phosphoproteins - drug effects | Mitogen-Activated Protein Kinase 1 - drug effects | Cholangiocarcinoma - metabolism | Chromatography, High Pressure Liquid | Diarrhea - chemically induced | Mitogen-Activated Protein Kinase 3 - drug effects | Pancreatic Neoplasms - drug therapy | Tandem Mass Spectrometry | Uterine Cervical Neoplasms - metabolism | Esophageal Neoplasms - metabolism | Adult | Female | Colorectal Neoplasms - metabolism | Bile Duct Neoplasms - drug therapy | Drug Eruptions - etiology | Abdominal Pain - chemically induced | Uterine Cervical Neoplasms - drug therapy | Glycogen Synthase Kinase 3 beta - metabolism | Mesothelioma - drug therapy | Cholangiocarcinoma - drug therapy | MAP Kinase Kinase 2 - antagonists & inhibitors | Protein Kinase Inhibitors - therapeutic use | Aged | Protein Kinase Inhibitors - pharmacology | Carcinoma, Non-Small-Cell Lung - drug therapy | Esophageal Neoplasms - drug therapy | Proto-Oncogene Proteins c-akt - drug effects | Care and treatment | Protein kinases | Mitogens | Cells | Tumors | Index Medicus
Journal Article
Gastroenterology, ISSN 0016-5085, 2014, Volume 147, Issue 5, pp. 1119 - 1133.e4
Background & Aims Although smoking is a leading risk factor for pancreatic ductal adenocarcinoma (PDAC), little is known about the mechanisms by which smoking... 
Gastroenterology and Hepatology | Metastasis | Pancreas | Progenitor Cells | Mouse Model | Gastroenterology & Hepatology | Life Sciences & Biomedicine | Science & Technology | Pancreatic Neoplasms - metabolism | Neoplastic Stem Cells - drug effects | Proto-Oncogene Proteins p21(ras) - genetics | Humans | Carcinoma, Pancreatic Ductal - metabolism | Epithelial-Mesenchymal Transition - drug effects | Mice, 129 Strain | Carcinoma, Pancreatic Ductal - genetics | Neoplastic Stem Cells - metabolism | Time Factors | Cell Transformation, Neoplastic - genetics | Neoplastic Stem Cells - pathology | Pancreatic Neoplasms - chemically induced | Liver Neoplasms - secondary | Nicotinic Agonists - toxicity | Proto-Oncogene Proteins c-akt - metabolism | Neoplastic Cells, Circulating - drug effects | GATA6 Transcription Factor - deficiency | Liver Neoplasms - genetics | Pancreatic Neoplasms - pathology | Pancreas - pathology | alpha7 Nicotinic Acetylcholine Receptor - genetics | Pancreas - metabolism | Mice, Knockout | Acinar Cells - pathology | Signal Transduction - drug effects | Mice, Nude | Liver Neoplasms - metabolism | Cell Line, Tumor | alpha7 Nicotinic Acetylcholine Receptor - metabolism | Mutation | Carcinoma, Pancreatic Ductal - secondary | Carcinoma, Pancreatic Ductal - chemically induced | Neoplastic Cells, Circulating - pathology | Neoplastic Cells, Circulating - metabolism | Cell Transformation, Neoplastic - chemically induced | Extracellular Signal-Regulated MAP Kinases - metabolism | Carcinoma, Pancreatic Ductal - prevention & control | Tumor Suppressor Protein p53 - genetics | Transfection | Proto-Oncogene Proteins p21(ras) - deficiency | Gene Expression Regulation, Neoplastic - drug effects | Pancreatic Neoplasms - prevention & control | Tumor Cells, Cultured | Proto-Oncogene Proteins p21(ras) - metabolism | Acinar Cells - metabolism | Cell Dedifferentiation - drug effects | Metformin - pharmacology | Mice, Inbred C57BL | Tumor Suppressor Protein p53 - metabolism | Pancreas - drug effects | Pancreatic Neoplasms - genetics | Nicotine - toxicity | Cell Transformation, Neoplastic - metabolism | Proto-Oncogene Proteins c-myc - metabolism | GATA6 Transcription Factor - metabolism | Animals | Acinar Cells - drug effects | GATA6 Transcription Factor - genetics | Cell Transformation, Neoplastic - pathology | Pancreatic cancer | Stem cells | Nicotine | Index Medicus | Abridged Index Medicus
Journal Article
Journal Article
by Wang-Gillam, Andrea and Li, Chung-Pin and Bodoky, György and Dean, Andrew and Shan, Yan-Shen and Jameson, Gayle and Macarulla, Teresa and Lee, Kyung-Hun and Cunningham, David and Blanc, Jean F and Hubner, Richard A and Chiu, Chang-Fang and Schwartsmann, Gilberto and Siveke, Jens T and Braiteh, Fadi and Moyo, Victor and Belanger, Bruce and Dhindsa, Navreet and Bayever, Eliel and Von Hoff, Daniel D and Chen, Li-Tzong and Adoo, Clarence and Anderson, Thomas and Asselah, Jamil and Azambuja, Alan and Bampton, Carolyn and Barrios, Carlos Henrique and Bekaii-Saab, Tanios and Bohuslav, Melichar and Chang, David and Chen, Jen-Shi and Chen, Yeu-Chin and Choi, Hye Jin and Chung, Ik Joo and Chung, Vincent and Csoszi, Tibor and Cubillo, Antonio and DeMarco, Linda and de Wit, Maike and Dragovich, Tomislav and Edenfield, William and Fein, Luis Enrique and Franke, Fábio and Fuchs, Martin and Gonzales-Cruz, Vega and Gozza, Alberto and Fernando, Rivera Herrero and Iaffaioli, Rosario and Jakesova, Jitka and Kahan, Zsuzsanna and Karimi, Misagh and Kim, Jun Suk and Korbenfeld, Ernesto and Lang, Istvan and Lee, Fa-Chyi and Lee, Kuan-Der and Lipton, Lara and Ma, Wen Wee and Mangel, Laszlo and Mena, Raul and Palmer, Daniel and Pant, Shubham and Park, Joon Oh and Piacentini, Paolo and Pelzer, Uwe and Plazas, Javier Gallego and Prasad, Cooray and Rau, Kun-Ming and Raoul, Jean-Luc and Richards, Donald and Ross, Paul and Schlittler, Luis and Smakal, Martin and Stahalova, Vladimira and Sternberg, Cora and Seufferlein, Thomas and Tebbutt, Niall and Vinholes, Jeferson Jose and Wadlow, Raymond and Wenczl, Milkos and Wong, Mark and NAPOLI-1 Study Group and NAPOLI-1 Study Grp
The Lancet (British edition), ISSN 0140-6736, 02/2016, Volume 387, Issue 10018, pp. 545 - 557
Summary Background Nanoliposomal irinotecan showed activity in a phase 2 study in patients with metastatic pancreatic ductal adenocarcinoma previously treated... 
Internal Medicine | Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Leucovorin - administration & dosage | Humans | Middle Aged | Male | Fatigue - chemically induced | Diarrhea - chemically induced | Pancreatic Neoplasms - drug therapy | Neoplasm Metastasis | Fluorouracil - administration & dosage | Leucovorin - adverse effects | Fluorouracil - adverse effects | Camptothecin - administration & dosage | Carcinoma, Pancreatic Ductal - mortality | Deoxycytidine - adverse effects | Female | Pancreatic Neoplasms - mortality | Neutropenia - chemically induced | Camptothecin - analogs & derivatives | Camptothecin - adverse effects | Deoxycytidine - administration & dosage | Kaplan-Meier Estimate | Treatment Outcome | Carcinoma, Pancreatic Ductal - drug therapy | Irinotecan | Vomiting - chemically induced | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Aged | Liposomes | Deoxycytidine - analogs & derivatives | Antimitotic agents | Medical colleges | Pancreatic cancer | Leucovorin | Product development | Research institutes | Metastasis | Antineoplastic agents | Analysis | Antigens | Chemotherapy | Medical prognosis | Clinical trials | Drug dosages | Cancer therapies | Tumors | Adenocarcinoma | Therapy | Gemcitabine | Toxicity | Evidence-based medicine | Metastases | Nanoparticles | Randomization | Vomiting | Safety management | Toxic diseases | Neutropenia | Folinic acid | Lymphatic system | Medical treatment | Diarrhea | FDA approval | Survival | Patients | Acids | Equivalence | Interactive systems | Index Medicus | Abridged Index Medicus
Journal Article
Journal of clinical oncology, ISSN 1527-7755, 05/2008, Volume 26, Issue 13, pp. 2124 - 2130
Journal Article
Journal Article